Key Investor Signals
Secured a place in BII’s €560,000 loan cohort
Alvara joined BioInnovation Institute’s September 2026 cohort, whose participants are each allocated a €560,000 convertible loan plus venture-development support.
Translated 11 years of Keap1 research into a venture
Co-founder Anders Bach’s Copenhagen group developed the Keap1 program over 11 years before spinning it into Alvara with medicinal chemist Marie Cadot.
Developed several cell-active Keap1 inhibitor series
The SPARK Denmark project describes multiple novel inhibitor series with high affinity, selectivity, cellular activity and drug-like properties for further kidney-disease work.
Other Positive Signals
- Built the research program with academic collaborators and contributions from AstraZeneca in Sweden.
Team
Marie Cadot
CEO and Co-founder
- Completed a Copenhagen PhD on structure-guided, fragment-derived Keap1 inhibitors, directly matching the company’s target.
- Trained as a pharmacist and medicinal chemist, with postdoctoral drug-design research at the University of Copenhagen.
- Completed a 2020 R&D internship at Novo Nordisk Pharmatech, developing synthesis and characterization methods.
Anders Bach
CSO and Co-founder
- Professor and group leader in medicinal chemistry at the University of Copenhagen, focused on disease-related protein interactions.
- Built an 11-year Keap1 research program, developing compound series that underpin the Alvara spinout.
- Developed fragment-based approaches and comparative assays to distinguish active Keap1 inhibitors from false-positive compounds.
Product
Alvara uses fragment-based drug discovery to build small-molecule inhibitors of Keap1–Nrf2. Small chemical fragments are screened for binding, examined structurally and developed into more potent compounds, with oral treatment as the intended product format.
Finding small chemical starting points
The discovery workflow screens libraries of low-complexity molecular fragments against the target. Sensitive biophysical methods identify weak binding that can provide a starting point for medicinal chemistry.
Using structure to improve compounds
Structural biology shows how each fragment sits in a protein pocket. The team uses that information to decide where to grow or link fragments, improving binding and other properties needed in a medicine.
Releasing a protective cellular response
The compounds are intended to disrupt Keap1’s interaction with Nrf2 without forming a permanent chemical bond. This can activate antioxidant and anti-inflammatory proteins, the biological rationale for kidney protection.
Market Overview
Chronic kidney disease creates a long-term treatment need across a large adult population, often alongside diabetes, hypertension and cardiovascular disease. Earlier-stage patients account for most cases. Drug development focuses on preserving kidney function before patients require dialysis or transplantation.
Renal medicine has attracted pharmaceutical acquisitions of both small-molecule and antibody developers. Alvara’s opportunity is a new protective mechanism within this established treatment field. A commercial program must show benefit beyond current care, with evidence on kidney function, progression and tolerability.
An estimated 788 million adults aged 20 and older had chronic kidney disease worldwide in 2023.
Chronic kidney disease caused an estimated 1.48 million deaths globally in 2023.
Impaired kidney function accounted for an estimated 11.5% of cardiovascular deaths in 2023.
The combined global prevalence of stage 1–3 chronic kidney disease was 13.9% among adults in 2023.
Comparable Outcomes
Chinook Therapeutics
Developed precision medicines for kidney diseases, including oral atrasentan and an antibody program for IgA nephropathy. Novartis completed the acquisition in August 2023 for $3.2 billion upfront, with up to $300 million in regulatory milestones.
Visterra
Developed engineered antibody therapies designed to target difficult proteins in infectious and kidney diseases. Otsuka agreed to acquire Visterra in July 2018 for approximately $430 million in cash, strengthening its kidney-disease pipeline.
Interested in More Startups Like Alvara Therapeutics?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.